Basilea Pharmaceutica
Grenzacherstrasse 487
Basel
CH-4005
Tel: 41-61-6061-111
Fax: 41-61-6061-112
Website: http://www.basilea.com/
About Basilea Pharmaceutica
Basilea Pharmaceutica is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through its fully integrated research and development operations the company focuses on the development of innovative antibiotics, antifungals and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options.YEAR FOUNDED:
October 17, 2000
LEADERSHIP:
Founder: Jan G. J. van de Winkel, Ph.D.
CEO: Ronald Scott
CMO (Medical): Achim Kaufhold
CTO: Günter Ditzinger
CFO: Donato Spota
CSO (Scientific): Laurenz Kellenberger
JOBS:
Please click here for.
CLINICAL TRIAL
Please click here for clinical trial information.
PRODUCTS:
All Products
270 articles about Basilea Pharmaceutica
-
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
4/9/2024
Basilea Pharmaceutica Ltd announced that it has been awarded a grant from CARB-X, a global non-profit partnership dedicated to supporting the early development of antibacterial products.
-
Basilea Pharmaceutica received FDA approval for its antibiotic Zevtera in three indications Wednesday, finally getting the drug across the finish line a decade and a half after the agency rejected an earlier submission.
-
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications
4/4/2024
Basilea Pharmaceutica Ltd, Allschwil announced that the US Food and Drug Administration approved ZEVTERA®, for the treatment of adult patients with Staphylococcus aureus bloodstream infections, including those with right-sided infective endocarditis, and adult patients with acute bacterial skin and skin structure infections and for adult and pediatric patients with community-acquired bacterial pneumonia.
-
April kicks off with three FDA target action dates, including one that could potentially set the stage to move CAR-T therapies into earlier lines of treatment.
-
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
3/11/2024
Basilea Pharmaceutica Ltd, Allschwil, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced that the continued strong sales performance of the antifungal Cresemba® by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 1.25 million milestone payment.
-
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio
2/13/2024
Basilea Pharmaceutica Ltd announced its results for the financial year ended December 31, 2023.
-
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
1/19/2024
Basilea Pharmaceutica Ltd. announced that the sales of the antifungal Cresemba® in 2023 by its partner Knight Therapeutics Inc. in Latin America exceeded the threshold triggering the first sales milestone payment for this region.
-
Basilea announces acquisition of preclinical antibiotics program from Spexis
1/15/2024
Basilea Pharmaceutica Ltd announced that it has entered into an asset purchase agreement with Spexis AG for a preclinical program of antibiotics from a novel class, targeting Gram-negative bacteria, including multidrug-resistant strains.
-
Basilea provides portfolio status update - Jan 05, 2024
1/5/2024
Basilea Pharmaceutica Ltd reported on the progress within its R&D portfolio in 2023 and upcoming milestones and timelines.
-
Basilea announces accelerated loan repayment
12/20/2023
Basilea Pharmaceutica Ltd, Allschwil, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced that it will accelerate the repayment of its senior secured loan.
-
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis
12/11/2023
Basilea Pharmaceutica Ltd announced that its license partner Astellas Pharma US, Inc. received the approval of Cresemba® for the treatment of invasive aspergillosis and invasive mucormycosis in pediatric patients by the US Food and Drug Administration.
-
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this year
11/20/2023
Basilea Pharmaceutica Ltd announced that the continued strong sales performance of the antifungal Cresemba® by its license partner Pfizer Inc.
-
Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal
11/13/2023
Basilea Pharmaceutica Ltd announced that it has entered into an asset purchase agreement with Amplyx Pharmaceuticals, Inc., an affiliate of Pfizer Inc., to acquire the rights to fosmanogepix, a clinical-stage broad-spectrum antifungal candidate.
-
Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agent
10/31/2023
Basilea Pharmaceutica Ltd announced that it has entered into an exclusive evaluation license and option agreement for tonabacase, with iNtRON Biotechnology, Inc., a company based in the Republic of Korea.
-
Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infections
10/19/2023
Basilea Pharmaceutica Ltd announced that it has entered into an asset purchase agreement with privately owned Gravitas Therapeutics Inc. for GR-2397, a clinical-stage antifungal compound with a novel mechanism of action, targeting invasive mold infections caused by Aspergillus species.
-
Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023
10/17/2023
Basilea Pharmaceutica Ltd, Allschwil, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced that scientific presentations with new data on its antibiotic ceftobiprole have been presented at Infectious Disease Week 2023, highlighting its utility for the treatment of severe bacterial infections.
-
Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole
10/2/2023
Basilea Pharmaceutica Ltd, Allschwil, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, announced that the US Food and Drug Administration has accepted for filing the New Drug Application for the antibiotic ceftobiprole, which was submitted to the FDA on August 3rd this year.
-
Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremia
9/28/2023
Basilea Pharmaceutica Ltd, Allschwil announced that data from the successful phase 3 study ERADICATE were published in the New England Journal of Medicine, one of the world's leading peer-reviewed medical journals.
-
Basilea reports strong revenue and profit growth in first half-year 2023
8/15/2023
Basilea Pharmaceutica Ltd, Allschwil, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, announced its financial results for the first half-year ended June 30, 2023.
-
Basilea announces submission of a New Drug Application to the US Food and Drug Administration for its antibiotic ceftobiprole
8/4/2023
Basilea Pharmaceutica Ltd, Allschwil, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced that it has submitted a New Drug Application to the US Food and Drug Administration.